Experimental acute myocardial infarction in rats: HIF-1α, caspase-3, erythropoietin and erythropoietin receptor expression and the cardioprotective effects of two different erythropoietin doses

Acta Histochemica

Volumn 115, Issue 7, 2013, Pages 658-668

  Guven Bagla, Aysel ^a   Ercan, Ertugrul ^b   Asgun, Halil Fatih ^a   Ickin, Meltem ^a   Ercan, Feriha ^c   Yavuz, Ozlem ^d   Bagla, Suat ^e   Kaplan, Askin ^f  

^a ÇANAKKALE ONSEKIZ MART UNIVERSITY   (Turkey)

^b IZMIR UNIVERSITY   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

^d BALIKESIR UNIVERSITY   (Turkey)

^e Provincial Directorate of Agriculture   (Turkey)

^f Family Medicine   (Turkey)

Author keywords

Caspase 3; Erythropoietin; Erythropoietin receptor; Hypoxia inducible factor 1 ; Myocardial infarction; Rat

Indexed keywords

BIOCHEMICAL MARKER; CASPASE 3; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RECOMBINANT ERYTHROPOIETIN; TRIPHENYLTETRAZOLIUM;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DRUG EFFECT; DRUG MEGADOSE; ELECTRON MICROSCOPY; HEART INFARCTION SIZE; HEART PROTECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; VASCULARIZATION; WISTAR RAT;

RATTUS; RATTUS NORVEGICUS;

CASPASE 3; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1Α; MYOCARDIAL INFARCTION; RAT;

ANIMALS; CARDIOTONIC AGENTS; CASPASE 3; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, WISTAR; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT PROTEINS;

EID: 84884530977     PISSN: 00651281     EISSN: 16180372     Source Type: Journal    
DOI: 10.1016/j.acthis.2013.01.005     Document Type: Article

References (44)

1. Ahmet I., Tae H.J., Juhaszova M., Riordon D.R., Boheler K.R., Sollott S.J., et al. A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage. Mol Med 2011, 17:194-200.
2. Akimoto T., Kusano E., Inaba T., Iimura O., Takahashi H., Ikeda H., et al. Erythropoietin regulates vascular smooth muscle cell apoptosis by a phosphatidylinositol 3 kinase-dependent pathway. Kidney Int 2000, 58:269-282.
3. Ammarguellat F., Llovera M., Kelly P.A., Goffin V. Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun 2001, 284:1031-1038.
4. Anagnostou A., Liu Z., Steiner M., Chin K., Lee E.S., Kessimian N., et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994, 91:3974-3978.
5. Azevedo Filho C.F., Hadlich M., Petriz J.L., Mendonça L.A., Moll Filho J.N., Rochitte C.E. Quantification of left ventricular infarcted mass on cardiac magnetic resonance imaging, Comparison between planimetry and the semiquantitative visual scoring Method. Arq Bras Cardiol 2004, 83:118-124. 111-117.
6. Ben-Dor I., Hardy B., Fuchs S., Kaganovsky E., Kadmon E., Sagie A., et al. Repeated low-dose of erythropoietin is associated with improved left ventricular function in rat acute myocardial infarction model. Cardiovasc Drugs Ther 2007, 21:339-346.
7. Brines M., Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006, 70:246-250.
8. Brines M., Grasso G., Fiordaliso F., Sfacteria A., Ghezzi P., Fratelli M., et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004, 101:14907-14912.
9. Brunner S., Huber B.C., Weinberger T., Vallaster M., Wollenweber T., Gerbitz A., et al. Migration of bone marrow-derived cells and improved perfusion after treatment with erythropoietin in a murine model of myocardial infarction. J Cell Mol Med 2012, 16:152-159.
10. Bullard A.J., Govewalla P., Yellon D.M. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 2005, 100:397-403.
11. Cai Z., Manalo D.J., Wei G., Rodriguez E.R., Fox-Talbot K., Lu H., et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003, 108:79-85.
12. Cai Z., Semenza G.L. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 2004, 109:2050-2053.
13. Calvillo L., Latini R., Kajstura J., Leri A., Anversa P., Ghezzi P., et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003, 100:4802-4806.
14. Chong Z.Z., Kang J.Q., Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 2002, 22:503-514.
15. Digicaylioglu M., Bichet S., Marti H.H., Wenger R.H., Rivas L.A., Bauer C., et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 1995, 92:3717-3720.
16. Digicaylioglu M., Lipton S.A. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001, 412:641-647.
17. Fiordaliso F., Chimenti S., Staszewsky L., Bai A., Carlo E., Cuccovillo I., et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 2005, 102:2046-2051.
18. Fisher J.W., Koury S., Ducey T., Mendel S. Erythropoietin production by interstitial cells of hypoxic monkey kidneys. Br J Haematol 1996, 95:27-32.
19. Guneli E., Cavdar Z., Islekel H., Sarioglu S., Erbayraktar S., Kiray M., et al. Erythropoietin protects the intestine against ischemia/reperfusion injury in rats. Mol Med 2007, 13:509-517.
20. Hanlon P.R., Fu P., Wright G.L., Steenbergen C., Arcasoy M.O., Murphy E. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 2005, 19:1323-1325.
21. Jelkmann W., Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 2004, 83:673-686.
22. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004, 43:649-659.
23. Junk A.K., Mammis A., Savitz S.I., Singh M., Roth S., Malhotra S., et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 2002, 99:10659-10664.
24. Lipsic E., Schoemaker R.G., van der Meer P., Voors A.A., van Veldhuisen D.J., van Gilst W.H. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006, 48:2161-2167.
25. Lipsic E., van der Meer P., Henning R.H., Suurmeijer A.J., Boddeus K.M., van Veldhuisen D.J., et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 2004, 44:473-479.
26. Marti H.H. Erythropoietin and the hypoxic brain. J Exp Biol 2004, 207:3233-3242.
27. Marzo F., Lavorgna A., Coluzzi G., Santucci E., Tarantino F., Rio T., et al. Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J Thromb Thrombolysis 2008, 26:183-187.
28. Moon C., Krawczyk M., Ahn D., Ahmet I., Paik D., Lakatta E.G., et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003, 100:11612-11617.
29. Mudalagiri N.R., Mocanu M.M., Di Salvo C., Kolvekar S., Hayward M., Yap J., et al. Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation. Br J Pharmacol 2008, 153:50-56.
30. Nakano M., Satoh K., Fukumoto Y., Ito Y., Kagaya Y., Ishii N., et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res 2007, 100:662-669.
31. Nangaku M., Eckardt K.U. Hypoxia and the HIF system in kidney disease. J Mol Med 2007, 85:1325-1330.
32. Ogilvie M., Yu X., Nicolas-Metral V., Pulido S.M., Liu C., Ruegg U.T., et al. Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 2000, 275:39754-39761.
33. Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003, 112:999-1007.
34. Paschos N., Lykissas M.G., Beris A.E. The role of erythropoietin as an inhibitor of tissue ischemia. Int J Biol Sci 2008, 4:161-168.
35. Rui T., Feng Q., Lei M., Peng T., Zhang J., Xu M., et al. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 2005, 65:719-727.
36. Sasaki R., Masuda S., Nagao M. Erythropoietin: multiple physiological functions and regulation of biosynthesis. Biosci Biotechnol Biochem 2000, 64:1775-1793.
37. Sharples E.J., Patel N., Brown P., Stewart K., Mota-Philipe H., Sheaff M., et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004, 15:2115-2124.
38. Solaroglu A., Dede F.S., Okutan E., Bayrak A., Haberal A., Kilinc K. A single dose of erythropoietin attenuates lipid peroxidation in experimental liver ischemia-reperfusion injury in the rat fetus. J Matern Fetal Neonatal Med 2004, 16:231-234.
39. Tramontano A.F., Muniyappa R., Black A.D., Blendea M.C., Cohen I., Deng L., et al. Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun 2003, 308:990-994.
40. Ueba H., Brines M., Yamin M., Umemoto T., Ako J., Momomura S., et al. Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin. Proc Natl Acad Sci USA 2010, 107:14357-14362.
41. Vivaldi M.T., Kloner R.A., Schoen F.J. Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. Am J Pathol 1985, 121:522-530.
42. Weidemann A., Johnson R.S. Biology of HIF-1 alpha. Cell Death Differ 2008, 15:621-627.
43. Wright G.L., Hanlon P., Amin K., Steenbergen C., Murphy E., Arcasoy M.O. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 2004, 18:1031-1033.
44. Wu H., Ren B., Zhu J., Dong G., Xu B., Wang C., et al. Pretreatment with recombined human erythropoietin attenuates ischemia-reperfusion-induced lung injury in rats. Eur J Cardiothorac Surg 2006, 29:902-907.